HER-2+ cancer immunotherapy that stimulates a polyclonal antibody response to HER-2


  1. Tobias J, Baier K, Ambroz K, Zielinski C, Wiedermann U.  Construction of a novel anti-Her-2/neu multi-level vaccine combining Trastuzumab and Pertuzumab binding site mimotopes together with anti-PD1 immune checkpoint inhibitor, Poster presentation by Joshua Tobias PhD, Keystone Symposia Cancer Immunotherapy Combinations March 23-27 2018 at Fairmont The Queen Elizabeth, Montreal, Québec, Canada.  Click here to view poster.

  2. Tobias J, Jasinska J, Baier K, Kundi M, Ede N, Zielinski C, Wiedermann U. Enhanced and long term immunogenicity of a Her-2/neu multi-epitope vaccine conjugated to the carrier CRM197 in conjunction with the adjuvant Montanide.  BMC Cancer. 2017 Feb 9;17(1):118. doi: 10.1186/s12885-017-3098-7.

  3. Hoos A, Britten C, The immuno-oncology framework: Enabling a new era of cancer therapy, Oncoimmunology. 2012 May 1;1(3):334-339

  4. Wiedermann U and C.C. Zielinski. Vaccination for prevention and treatment of breast cancer. Breast Cancer Res Treat. 2013 Feb;138(1):1-12
  5. Wiedermann U, C. Wiltschke, J. Jasinska, M. Kundi, R. Zurbriggen, E. Garner-Spitzer. R. Bartsch, G. Steger, H. Pehamberger, O. Scheiner, C.C. Zielinski. 2010. A virosomal formulated Her-2/neu multi-peptide vaccine induces Her-2/neu specific immune responses in patients with metastatic breast cancer: a phase I study. Breast Cancer Res Treat. 119 (3):673-83.
  6. Wagner S, C. Krepler, D. Allwardt, J. Latzka, S. Strommer, O. Scheiner, H. Pehamberger, U. Wiedermann, C. Hafner, and H. Breiteneder. 2008. Reduction of human melanoma tumor growth in severe combined immunodeficient mice by passive transfer of antibodies induced by a high molecular weight melanoma-associated antigen mimotope vaccine. Clin Cancer Res.;14(24):8178-83.
  7. Wagner, S.; J. Jasinska, H. Breiteneder, M. Kundi, H. Pehamberger, O. Scheiner, C. C. Zielinski, and U. Wiedermann. 2007. Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice. Breast Cancer Res Treat. 2007 Jan 3; 106(1):29-38.
  8. Brämswig KH, Knittelfelder R, Gruber S, Untersmayr E, Riemer AB, Szalai K, Horvat R, Kammerer R, Zimmermann W, Zielinski CC, Scheiner O, Jensen-Jarolim E. Immunization with mimotopes prevents growth of carcinoembryonic antigen positive tumors in BALB/c mice. Clin Cancer Res. 2007 Nov 1;13(21):6501-8.
  9. Riemer AB, Untersmayr E, Knittelfelder R, Duschl A, Pehamberger H, Zielinski CC, Scheiner O, Jensen-Jarolim E. Active induction of tumor-specific IgE antibodies by oral mimotope vaccination. Cancer Res. 2007 Apr 1;67(7):3406-11.
  10. Hafner, C.; H. Breiteneder, S. Ferrone, C. Thallinger, S. Wagner, W. M. Schmidt, J. Jasinska, M. Kundi, K. Wolff, C. C. Zielinski, O. Scheiner, U. Wiedermann*, and H. Pehamberger. 2005. Suppression of human melanoma tumor growth in SCID mice by a human high molecular weight-melanoma associated antigen (HMW-MAA) specific monoclonal antibody. Int J Cancer, 114:426.
  11. Wagner, S.; C. Hafner, D. Allwardt, J. Jasinska, S. Ferrone, C. C. Zielinski, O. Scheiner, U. Wiedermann, H. Pehamberger, and H. Breiteneder. 2005. Vaccination with a human high molecular weight melanoma-associated antigen mimotope induces a humoral response inhibiting melanoma cell growth in vitro. J Immunol,  174:976.
  12. Hafner, C., S. Wagner, J. Jasinska, D. Allwardt, O. Scheiner, K. Wolff, H. Pehamberger, U. Wiedermann, and H. Breiteneder. 2005. Epitope-specific antibody response to Mel-CAM induced by mimotope immunization. J Invest Dermatol,  124:125.
  13. Riemer AB, Kurz H, Klinger M, Scheiner O, Zielinski CC, Jensen-Jarolim E. Vaccination with cetuximab mimotopes and biological properties of induced anti-epidermal growth factor receptor antibodies. J Natl Cancer Inst. 2005 Nov 16;97(22):1663-70.
  14. Riemer AB, Kraml G, Scheiner O, Zielinski CC, Jensen-Jarolim E: Matching of trastuzumab (Herceptin) epitope mimics onto the surface of Her-2/neu–a new method of epitope definition. Molecular Immunology 2005, 42(9):1121-1124.
  15. JasinskaJ, WagnerS, RadauerC, SedivyR, BrodowiczT, WiltschkeC, Breiteneder H, Pehamberger H, Scheiner O, WiedermannU*, Zielinski CC. Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu. Int. J. Cancer. 2003.  20; 107:976-83.
  16. Riemer AB, Hantusch B, Sponer B, Kraml G, Hafner C, Zielinski CC, Scheiner O, Pehamberger H, Jensen-Jarolim E.High-molecular-weight melanoma-associated antigen mimotope immunizations induce antibodies recognizing melanoma cells. Cancer Immunol Immunother. 2005 Jul;54(7):677-84. Epub 2004 Nov 24.
  17. Riemer AB, Klinger M, Wagner S, Bernhaus A, Mazzucchelli L, Pehamberger H, Scheiner O, Zielinski CC, Jensen-Jarolim E: Generation of Peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. J Immunol 2004, 173(1):394-401.



© Imugene 2018. All rights reserved. ABN 99 009 179 551